Bio-Rad Laboratories Inc BIO.B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BIO.B is a good fit for your portfolio.
News
-
Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
-
Bio-Rad’s Chief Operating Officer Andrew Last to Retire
-
Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results
-
Bio-Rad's stock leads the S&P 500 decliners, as they suffer the biggest selloff in 36 years after disappointing results.
Trading Information
- Previous Close Price
- $278.55
- Day Range
- $276.60–276.60
- 52-Week Range
- $275.55–417.25
- Bid/Ask
- $273.91 / $275.60
- Market Cap
- $7.89 Bil
- Volume/Avg
- 6 / 332
Key Statistics
- Price/Earnings (Normalized)
- 23.36
- Price/Sales
- 3.06
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 5.40%
Company Profile
Bio-Rad Laboratories Inc manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. It operates in two industry segments; In Clinical Diagnostics segment, the company manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In Life Sciences segment, the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with majority of the revenue being generated from United States, it also has its presence in Europe, Asia, Canada and other regions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Mid Core
- Total Number of Employees
- 8,030
- Website
- https://www.bio-rad.com
Comparables
Valuation
|
Metric
|
BIO.B
|
TECH
|
TIHE
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.36 | 33.60 | — |
Price/Book Value | 0.91 | 5.08 | — |
Price/Sales | 3.06 | 8.96 | — |
Price/Cash Flow | 10.12 | 31.28 | — |
Price/Earnings
BIO.B
TECH
TIHE
Financial Strength
|
Metric
|
BIO.B
|
TECH
|
TIHE
|
|---|---|---|---|
Quick Ratio | 4.01 | 2.54 | — |
Current Ratio | 5.83 | 4.37 | — |
Interest Coverage | −18.24 | 18.34 | — |
Quick Ratio
BIO.B
TECH
TIHE
Profitability
|
Metric
|
BIO.B
|
TECH
|
TIHE
|
|---|---|---|---|
Return on Assets (Normalized) | 2.73% | 11.61% | — |
Return on Equity (Normalized) | 3.84% | 15.75% | — |
Return on Invested Capital (Normalized) | 2.95% | 13.09% | — |
Return on Assets
BIO.B
TECH
TIHE
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Pvqqxgkx | Tggdhnc | $185.5 Bil | |
SYK
| Stryker Corp | Ngdbkdjnwx | Snxl | $128.2 Bil | |
MDT
| Medtronic PLC | Nvzpzdwg | Tfczhq | $106.7 Bil | |
BSX
| Boston Scientific Corp | Fhlyntlq | Mzgyhw | $99.0 Bil | |
DXCM
| DexCom Inc | Pfflrxxql | Frzy | $53.1 Bil | |
EW
| Edwards Lifesciences Corp | Vzgkwqpcg | Wpjqc | $52.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Bxvqbykk | Jgc | $24.9 Bil | |
ALGN
| Align Technology Inc | Nklchqj | Zyhws | $23.5 Bil | |
PHG
| Koninklijke Philips NV ADR | Fsrpdqh | Jdfft | $18.9 Bil | |
PODD
| Insulet Corp | Njtddpqzc | Dnybcy | $11.7 Bil |